MUFG Securities EMEA plc increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1,683.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,880 shares of the biopharmaceutical company’s stock after acquiring an additional 99,000 shares during the quarter. MUFG Securities EMEA plc’s holdings in Gilead Sciences were worth $8,497,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Welch Investments LLC acquired a new position in Gilead Sciences in the third quarter valued at approximately $108,000. Horan Capital Advisors LLC. bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $147,000. Hanson & Doremus Investment Management increased its holdings in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 480 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up $1.03 on Wednesday, reaching $81.82. The company had a trading volume of 7,060,000 shares, compared to its average volume of 10,070,000. The stock has a market cap of $106,850.00, a PE ratio of 23.51, a price-to-earnings-growth ratio of -1.83 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.70 EPS. research analysts predict that Gilead Sciences, Inc. will post 6.24 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a $0.57 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 59.77%.
Several equities research analysts have recently commented on GILD shares. William Blair restated a “buy” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Mizuho upped their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $73.67 to $94.00 in a report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $87.04.
In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the transaction, the insider now owns 3,070,099 shares in the company, valued at $230,196,023.02. The disclosure for this sale can be found here. Insiders sold a total of 418,333 shares of company stock worth $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by MUFG Securities EMEA plc” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/mufg-securities-emea-plc-grows-position-in-gilead-sciences-inc-gild-2.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.